Protagonist unveils ‘triple-G’ obesity pill, but human trials are nearly a year awaynews2025-06-30T20:05:58+00:00June 30th, 2025|Endpoints News|
Pfizer ends Phase 2 trial for final Trillium CD47 drugnews2025-06-30T19:50:20+00:00June 30th, 2025|Endpoints News|
Arcturus claims Phase 2 success in first data since shift to mRNA therapeuticsnews2025-06-30T18:51:17+00:00June 30th, 2025|Endpoints News|
CBER chief Prasad details why he overrode Novavax reviewersnews2025-06-30T17:26:07+00:00June 30th, 2025|Endpoints News|
Khosla Ventures backs ‘therapeutic plasma exchange’ startup Circulate Healthnews2025-06-30T17:00:26+00:00June 30th, 2025|Endpoints News|
Amgen’s stomach cancer drug boosts survival in Phase 3, but side effects leave questionsnews2025-06-30T15:23:41+00:00June 30th, 2025|Endpoints News|
Moderna reports Phase 3 flu data, teeing up new submissionsnews2025-06-30T11:00:29+00:00June 30th, 2025|Endpoints News|
FDA extends impurity data submission deadline for drugmakersnews2025-06-27T17:47:17+00:00June 27th, 2025|Endpoints News|
FDA loosens safety requirements for CAR-Ts in move to boost accessnews2025-06-27T17:07:11+00:00June 27th, 2025|Endpoints News|
Alphabet’s Calico inks $25M licensing deal for Mabwell’s IL-11 programsnews2025-06-27T11:08:00+00:00June 27th, 2025|Endpoints News|
